A total of 2259 urine samples were assayed for lysergic acid diethylamide (LSD) using radioimmunoassay (RIA, Coat-a-Count, Diagnostics Products) and a premarket cloned enzyme donor immunoassay (CEDIA, Boehringer Mannheim). Urine samples were obtained from patients admitted to the emergency room, patients in drug rehabilitation programs, and adults and juveniles in criminal probation programs. An overall incidence of positive results was 0.80% for CEDIA (500-pg/mL cutoff) and 0.89% and 0.18% for RIA at cutoffs of 250 and 500 pg/mL, respectively. Of the CEDIA-positive samples, only 17 and 11% were positive by RIA at 250 and 500 pg/mL, respectively, whereas among RIA-positive samples, only 10% of those > 250 pg/mL and only 25% of those > 500 pg/mL were positive by CEDIA. Moreover, only 2 of 25 of samples positive by one of these screening assays were confirmed by gas chromatography-mass spectrometry (GC-MS). It is likely that discrepancies in results between immunoassays are due to differences in antibody specificities used to detect LSD metabolites. in addition, immunoassays may be more sensitive than GC-MS for detecting LSD use as current confirmation assays are targeted towards detection of the parent drug only. The interpretation of results for LSD analysis must be made with knowledge of the limitations for each assay.
Introduction
Lysergic acid diethylamide (LSD) is a powerful hallucinogenic drug in the serotonin class of psychedelics (1) . Surveys have shown that high school and college students report the highest usage of LSD. Of subjects 18-25 years old, 11.1% reported having used LSD at least once, and 3.3% have used it within the past year (2) . The corresponding figures for subjects 26-34 years of age are 12.4% and 0.5%. One group of investigators reported an LSD prevalence among high school students of 5.6% in 1992 (3), whereas among college students, a prevalence as high as 17% in a southern university has been reported (4) . In drug-related emergency department (ED) visits, a low but steady frequency of LSD usage has been documented by The Drug Abuse Warning Network (DAWN) (5) . From 1988 to 1993, the prevalence of LSD-related ED visits ranged from 0.0015 to 0.0018%.
The active form of LSD is the d-isomer that has a molecular weight of 323 Daltons. LSD has a half-life of about 3-4 h and a volume of distribution of 0.28 L/kg (1) . Approximately 90% of LSD is bound to plasma proteins. Blood and urine concentrations of LSD following confirmed use have been studied by a number of investigators. Aghajanian et al. (6) found that after a 2-1Jg/kg dose, blood concentrations of LSD peaked at 5 ng/mL after I h and declined to I ng/mL after 8 h. Vu-Duc et al. (7) used RIA and found positive urine results for LSD at a cutoff of 0.1 ng/mL for 3 days after a 50-1Jg dose. Using HPLC with fluorescence detection, McCarron et al. (8) found positive urine results exceeding 0.5 ng/mL for at least 11 h after use. The LSD values in urine ranged from 0.2 to 7.7 ng/mL. These latter two studies suggest that urine is a reasonable specimen for detecting recent LSD use by the donor.
Sensitive assays for LSD and its metabolites have been developed using liquid chromatography-mass spectrometry and gas chromatography-tandem mass spectrometry (GC-MS-MS) (9, 10) . However, routine GC-MS assays are targeted for detection of the parent compound alone. Commercial isotopic and nonisotopic immunoassays have been available for several years. Antibodies used in these assays are raised against the parent drug, but, like other immunoassays for drugs of abuse, the LSD assay is likely to be sensitive to a variety of different unidentified metabolites. The purposes of this study were to examine the prevalence of LSD usage in various subject populations and to compare results of immunoassays with each other and with GC-MS.
Experimental

Assays
The Coat-A-Count radioimmunoassay (RIA) for LSD was obtained from Diagnostic Products Corporation (DPC, Los Angeles, CA). This assay was performed in the quantitative Reproduction (photocopying) of editorial content of this journal is prohibited without publisher's permission. mode using calibrators ranging from 0 to 3000 pg/mL. LSD cutoff concentrations of 250 and 500 pg/mL were evaluated in this study. This solid-phase RIA makes use of 12~I-labeled LSD, which competes with LSD from the urine sample for binding onto an immobilized LSD-specific antibody. After a 2-h incubation, the radioactivity of bound LSD tracer was measured using a ?-counter (model 1277, Wallace, Gaithersburg, MD). A premarket cloned enzyme donor immunoassay (CEDIA) was obtained from Boehringer Mannheim (BMC, Concord, CA). Subsequent to this study, this assay received approval by the Food and Drug Administration and is now commercially available. The general principles of CEDIA were presented previously (11) . The CEDIA LSD assay was performed in the qualitative mode with a cutoff concentration of 500 pg/mL. The threshold calibrator was set at a zero rate. This assay requires the use of three reagents and was adapted for automated analysis onto the BMC/Hitachi 911 analyzer (BMC, Indianapolis, IN).
GC-MS was performed on a subset of urine samples that were positive by immunoassay. In some cases, an insufficient volume of urine prohibited confirmation analysis. All quantitative CC-MS analyses were performed at MedTox Laboratories (St. Paul, MN). The assay was based on a modification of the LSD assay described by Francom et al. (12) . Standards, controls, and unknowns were alkalinized and extracted into butyl chloride. A trimethylsilyl derivative was prepared and analyzed by GC-MS (M + = 395). Quantitation for controls and unknowns is obtained from the standard-internal standard linear leastsquares regression line. Unknown specimens greater than or equal to the limit of quantitation and meeting retention time and qualifying ion ratio criteria were reported as positive. The limits of detection and quantitation are 0.10 and 0.25 ng/mL, respectively. LSD metabolites were not identified or quantitared in this confirmation assay.
Urine samples
The protocol for the use of urine samples was reviewed and approved by the respective Institutional Review Boards at Hartford Hospital and the University of Texas Health Science Center. All subjects were identified by number, and informed consent was deemed unnecessary. A total of 2259 urine samples were tested in this study. Of these, 640 samples were obtained from consecutive patients admitted to the Emergency Department of Hartford Hospital (Hartford, CT) for emergency drug screen analysis that included cocaine, barbiturates, benzodiazepines, opiates, cannabinoids, and amphetamines. Both negative and positive samples for these drugs were used in the analysis for LSD. For ED patients, the only criterion for entry into this study was an order for a urine drug screen that was due to a suspicion of drug use and enough leftover urine present for the LSD analysis. A total of 570 samples were also obtained from the drug rehabilitation program administered by Hartford Hospital's psychiatric unit (The Institute of Living, Hartford, CT). Urine specimens (350) were obtained from adults and juveniles who were in criminal probation programs in the state of Connecticut. These latter samples were originally tested for drugs of abuse at the Graham Massey Laboratory (Bridgeport, CT). The remaining 699 samples were submitted to the Hermann Hospital (Houston, TX) for drug analysis and include patients from the emergency department, obstetrical patients, and those enrolled in drug rehabilitation programs. The assay for LSD was not part of the normal testing protocol for any of these subject groups.
After routine testing for the ordered drug tests, urine specimens were stored for up to one week at refrigerated temperatures and then kept frozen at-20~ for up to six months before testing. All samples were thawed and tested by both RIA and CEDIA on the same day. Positive samples were then refrozen and sent in a batch to MedTox Laboratories for GC-MS confirmation analysis. 
Results
The within-run and day-to-day precision of the CEDIA assay are shown in Table I . The standard deviations and coefficients of variation (CV) were well within manufacturer's specifications. Table II lists the prevalence of LSD in various subject populations. The highest incidence of LSD positive results was observed in the two hospita]ized patient categories (1.1%). Lower incidences were observed in subjects enrolled in drug rehabilitation and probation programs. For CEDIA, the absorbance rate values for positive results ranged from 2 to 69 AmAU/min. Positive RIA values ranged from 254 to 14,900 pg/mL. For RIA, lowering the cutoff concentration increased the overall positive detection rate from 0.18% to 0.89%, as would be expected. The percentage concordance among positive samples between CEDIA and RLA at either cutoff concentration was poor. For the 18 urine specimens positive for CEDIA, only 2 (11%) and 3 (17%) were positive by RIA using the 500-and 250-pg/mL cutoff concentrations, respectively. Likewise among the 4 and 20 urine samples positive by RIA (500 and 250 pg/mL cutoffs, respectively), only 1 (25%) and 2 (10%) were positive by CEDIA. Of the 35 samples positive by one or more of the immunoassays, 25 were tested again by GC-MS. Of this group, only two were positive for LSD at a cutoff of 200 pg/mL. Table III lists results of urine samples for which data using all three methodologies were available.
Discussion
In this study, an overall LSD prevalence of 0.8-0.9% was reported in different testing populations using an immunoassay for screening of urine, which is roughly consistent with national surveys of recent LSD use among subjects aged 18 to 34. When considering the association of LSD use and ED visits, these results are considerably higher than values reported by the DAWN (5). The DAWN data are falsely low because hospital emergency departments do not routinely screen urine for the presence of LSD; thus, the true incidence is largely unknown. The hitherto absence of an automated nonisotopic immunoassay has limited the ability of EDs and laboratories to perform such testing in real time. This study showed that LSD had a higher prevalence among hospitalized patients than what was previously reported for PCP (0.15%) and had a prevalence equal to that of amphetamines (0.86%) (13) .
There have been several other studies comparing the performance of nonisotopic immunoassays for LSD with RIA, producing varying degrees of agreement among positive results. In one study of 35 urine samples, 88% concordance was observed between CEDIA and GC-MS-MS, and 100% concordance was observed between RIA and CEDIA (14) . In that study, only samples with positive GC-MS results were compared; thus, they all had high concentrations of the parent drug. In the study by McNally et al. (15) , there was an 82% concordance rate among positive samples between a commercial RIA assay and a nonisotopic immunoassay developed by the same manufacturer (Roche Diagnostics, Somerville, NJ). Although the antibodies used in these assays were not identical, they were raised against structurally similar immunogens, and a high concordance rate was not unexpected. In the study of Cassells et al. (16) , a concordance rate of 85% was observed between RIA (DPC) and a microplate enzyme immunoassay. In contrast with these studies, Cody et al. (17) found significant differences between two RIA assays (DPC and Roche) when nonhuman primates were given a 2 ]Jg/kg dose of LSD.
A major concern with interpreting results of different LSD immunoassays is the absence of available GC-MS confirmation procedures that are targeted toward LSD metabolites. LSD has a biological half-life of about 3 h and is metabolized by Ndemethylation (N-demethyl-LSD), N-deethylation (N-desethyl-LSD), and hydroxytation (13-hydroxy-LSD and 14-hydroxy-LSD) to inactive metabolites. Recently, two new metabolites of LSD, lysergic acid ethylvinylamide and 2-oxo-LSD, were identified by capillary electrophoresis-tandem mass spectrometry (18) . Only a small amount of LSD is excreted into the urine unchanged (19) . Thus, even with very sensitive assays, the window for detecting LSD use is very short. LSD metabolites have a longer biological half-life; therefore, it is not surprising that GC-MS confirmation results were negative on samples that were initially positive by immunoassay. The low rate of GC-MS confirmation observed in this study was not due to degradation of storage because LSD has shown to be very stable when frozen (20) .
It may be possible that the mode of immunoassay testing (i.e., qualitative CEDIA and quantitative RIA) had a role in producing these discordant results. Data in Table III showed, however, that in the majority of cases, specimens with positive results by CEDIA did not have quantitative results that were at -41  257  negative  -39  276  negative  -37  254  negative  -32  256  negative  -31  277  negative  -30  263  negative  -28  280  negative  -5  523  negative  2  87  negative  6  111  negative  9  31  negative  9  127  negative  9  902  negative  12  70  negative  20  89  negative  21  66  negative  39  151  negative  41  33  negative  41  44  negative  48  83  negative  59  200  negative  63  14,995  4400  66  455  1590  69 114 negative * For CEDIA, the rate for the cutoff calibrator (500 ng/mL) was set at zero. For RIA, positive quantitative results are set to a cutoff of 250 pg/mL.
or near the RIA cutoff concentration. Likewise, specimens with positive RIA results did not have AmAU/min rates that were near the cutoff values for CEDIA. The lack of concordance between immunoassays most likely occurred because the immunoassays cross-react to different LSD metabolites. In crossreactivity studies conducted by the manufacturer, common therapeutic drugs and drugs of abuse and LSD-like substances such as ergotamine, ~-ergocryptine, lysergic acid, and serotonin did not produce any significant crossreactivities (13) . However, because the metabolism of LSD is not well-defined, crossreactivity studies to LSD metabolites have not been fully documented.
Conclusion
With the development of more automated immunoassay methods for screening, consideration should be given for routine LSD testing in urine of select populations. The LSD assay could be added to a "stimulants and hallucinogens" panel which might include amphetamines, phencyclidines, and marijuana and may be helpful in explaining unusual or hallucinogenic behavior. For drug rehabilitation, this assay would give a more complete evaluation of the effectiveness of the program. In forensic toxicology, testing for LSD may be helpful in identifying drug use as a contributor to death. For workplace testing, the combination of the screening assay with GC-MS would allow for detection of positive samples only if urine is sampled reasonably soon after drug use. When the metabolism of LSD in humans is further defined, more useful confirmation assays could be developed that are targeted to specific metabolites, thereby enabling more effective confirmation of screening results.
